Tarsus Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $451.4 | $183.0 | $17.4 | $25.8 | $57.0 |
| Operating income | -$71.0 | -$120.6 | -$143.2 | -$62.7 | -$12.2 |
| Net income | -$66.4 | -$115.6 | -$135.9 | -$62.1 | -$13.8 |
| Balance Sheet | |||||
| Total debt | $75.0 | $75.0 | $30.0 | $20.0 | — |
| Cash Flow Statement | |||||
| Free cash flow | -$22.3 | -$84.6 | -$119.0 | -$49.5 | $3.2 |
Shares outstanding 43.9M · Free float 79.3%
Annual filing data through FY ended December 31, 2025; float as of September 13, 2026.